gpc2 car t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 30, 2023 (NCT05650749)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glypican-3Immunity, passive
GPC3 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07087002 | Phase 1 | Aug 28, 2025 | Stanford University |
| NCT05650749 | Phase 1 | Jan 30, 2023 | Tmunity Therapeutics, University of Pennsylvania |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Tmunity Therapeutics | For profit | 1 | 0 | 1 | 2023 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1